Wayne Kuznar, Medical Writer

Many patients who chose mastectomy were not at increased breast-cancer risk and may have done so based on a failed attempt at breast-conservation surgery.

Doubling the dose of fulvestrant increases the time to disease progression in the treatment of postmenopausal women with breast cancer.

About 10 months of neoadjuvant letrozole is optimal for breast-conserving surgery in patients with early breast cancer.

Lung cancer deaths are significantly less common in breast cancer patients who are treated with anti-estrogens.

A study reveals a beneficial effect of tamoxifen on breast cancer recurrences at 10 and 15 years of follow-up in women with ductal carcinoma in situ (DCIS).